Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally

Brain

Volumn 137, Issue 4, 2014, Pages 1120-1129

  Hanganu, Alexandru ^a   Bedetti, Christophe ^a,b   Degroot, Clotilde ^a,c   Mejia Constain, Béatriz ^a   Lafontaine, Anne Louise ^d   Soland, Valérie ^e   Chouinard, Sylvain ^e   Bruneau, Marie Andrée ^a   Mellah, Samira ^a   Belleville, Sylvie ^a,f   Monchi, Oury ^a,c  

^a CENTRE DE RECHERCHE   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

corticometry; longitudinal; magnetic resonance imaging; mild cognitive impairment; Parkinson's disease

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN CORTEX; BRAIN CORTEX ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; GRAY MATTER; HUMAN; INFERIOR FRONTAL GYRUS; LEARNING; LEFT HEMISPHERE; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; NUCLEUS RAPHE PALLIDUS; PARKINSON DISEASE; PRIORITY JOURNAL; RIGHT HEMISPHERE; SUPPLEMENTARY MOTOR AREA; TEMPORAL GYRUS; UNIFIED PARKINSON DISEASE RATING SCALE; WECHSLER MEMORY SCALE; AGED; ATROPHY; COMPLICATION; IMAGE PROCESSING; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PSYCHOLOGY;

AGED; ATROPHY; CEREBRAL CORTEX; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 84897901896     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu036     Document Type: Article

References (87)

1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289: 18-22.
2. Abe Y, Kachi T, Kato T, Arahata Y, Yamada T, Washimi Y, et al. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry 2003; 74: 419-22.
3. Agosta F, Canu E, Stefanova E, Sarro L, Tomić A, Spica V, et al. Mild cognitive impairment in Parkinson's disease is associated with a distributed pattern of brain white matter damage. Hum Brain Mapp 2013, [Epub ahead of print].
4. Alheid GF, Heimer L. New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: The striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 1988; 27: 1-39.
5. Bernhardt BC, Worsley KJ, Kim H, Evans AC, Bernasconi A, Bernasconi N. Longitudinal and cross-sectional analysis of atrophy in pharmacoresis-tant temporal lobe epilepsy. Neurology 2009; 72: 1747-54.
6. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-5.
7. Buckner RL, Head D, Parker J, Fotenos AF, Marcus D, Morris JC, et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage 2004; 23: 724-38.
8. Burgess PW, Shallice T, editors. The hayling and brixton tests. Test manual. Bury St Edmunds: Thames Valley Test Company; 1997.
9. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127: 791-800.
10. Caballol N, Martí MJ, Tolosa E. Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 2007; 22: S358-66.
11. Carlsen J, Heimer L. The basolateral amygdaloid complex as a cortical-like structure. Brain Res 1988; 441: 377-80.
12. Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 2008; 70: 828-33.
13. Culbertson CW, Zillmer EA, editors. Tower of London Drexel University (TOL DX). North Tonawanda, NY: Multi-Health Systems Incorporated (MHS); 2005.
14. Dale AM, Fischl B, Sereno MI. Cortical surface-based snalysis: I. Segmentation and surface reconstruction. Neuroimage 1999; 9: 179-94.
15. Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, et al. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain 2007; 130: 1159-66.
16. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314-24.
17. Ekman U, Eriksson J, Forsgren L, Mo SJ, Riklund K, Nyberg L. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012; 11: 679-87.
18. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-707.
19. Epstein J, Pan H, Kocsis J, Yang Y, Butler T, Chusid J, et al. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry 2006; 163: 1784-90.
20. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci 1999; 877: 412-38.
21. Farley I, Price K, Hornykiewicz O. Dopamine in thelimbic regions of the human brain: normal and abnormal. Adv Biochem Psychopharmacol 1977; 16: 57-64.
22. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-45.
23. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000; 97: 11050-5.
24. Fischl B, Sereno MI, Dale AM. Cortical surface-based snalysis: II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999; 9: 195-207.
25. Fischl B, Salat DH, van der Kouwe AJW, Makris N, Ségonne F, Quinn BT, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004; 23 (Suppl 1): S69-S84.
26. Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol 2008; 67: 1205-12.
27. Geng D-Y, Li Y-X, Zee C-S. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 2006; 58: 256-62.
28. Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 2002; 15: 870-8.
29. Golden CJ, Freshwater SM, editors. Stroop color and word test: a manual for clinical and experimental uses. Wood Dale, IL: Stoelting Co; 1998.
30. Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, Czanner S, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006; 32: 180-94.
31. Hanganu A, Bedetti C, Jubault T, Gagnon J-F, Mejia-Constain B, Degroot C, et al. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Mov Disord 2013; 28: 1360-9.
32. Heimer L, Alheid GF, De Olmos J, Groenewegen HJ, Haber SN, Harlan RE, et al. The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci 1997; 9: 354-81.
33. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70: 734-8.
34. Hooper HE. The Hooper Visual organization test. Los Angeles, CA: Western Psychological Services; 1958.
35. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
36. Husárová I, Mikl M, Lungu OV, Marecek R, Vanícek J, Bares M. Similar circuits but different connectivity patterns between the cerebellum, basal ganglia, and supplementary motor area in early Parkinson's disease patients and controls during predictive motor timing. J Neuroimaging 2013; 23: 452-62.
37. Joanette Y, Ska B, Côté H, editors. Protocole montréal d'évaluation de la communication (Protocole MEC). Isbergues, France: Ortho Edition; 2004.
38. Jubault T, Gagnon J-F, Karama S, Ptito A, Lafontaine A-L, Evans AC, et al. Patterns of cortical thickness and surface area in early Parkinson's disease. Neuroimage 2011; 55: 462-7.
39. Kaplan E, Goodglass H, Weintraub S, editors. Boston naming test. Philadelphia: Lea & Febiger; 1983.
40. Karagulle Kendi AT, Lehericy S, Luciana M, Ugurbil K, Tuite P. Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008; 29: 501-5.
41. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-13.
42. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 318: 876-80.
43. Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, Ozawa F, et al. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 2003; 60: 878-88.
44. Laakso MP, Partanen K, Riekkinen P, Lehtovirta M, Helkala E-L, Hallikainen M, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia. Neurology 1996; 46: 678-81.
45. Lerch JP, Evans AC. Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage 2005; 24: 163-73.
46. Lerch JP, Pruessner J, Zijdenbos AP, Collins DL, Teipel SJ, Hampel H, et al. Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls. Neurobiol Aging 2008; 29: 23-30.
47. Levin BE, Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Adv Neurol 2005; 65: 85-95.
48. Lisanby S, McDonald W, Massey E, Doraiswamy P, Rozear M, Boyko O, et al. Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. J Neural Transm Suppl 1993; 40: 13-21.
49. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012; 27: 349-56.
50. Lyoo CH, Ryu YH, Lee MS. Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia. Mov Disord 2010; 25: 496-9.
51. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee J-Y, Kim SJ, et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord 2006; 8: 65-74.
52. Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter atrophy in cognitively impaired Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83: 188-94.
53. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009; 44: 1415-22.
54. Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980; 14: 69-97.
55. Monastero R, Fiore P, Ventimiglia G, Camarda R, Camarda C. The neuropsychiatric profile of Parkinson's disease subjects with and without mild cognitive impairment. J Neural Transm 2013; 120: 607-11.
56. Mountcastle VB. The columnar organization of the neocortex. Brain 1997; 120: 701-22.
57. Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65: 1239-45.
58. Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, et al. Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 2008; 22: 557-64.
59. Nagano-Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64: 224-9.
60. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9.
61. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117-21.
62. Parent A, Carpenter MB, editors. Human neuroanatomy. Baltimore, MD: Williams & Wilkins; 1995.
63. Pearson K. Mathematical contributions to the theory of evolution.-On a form of spurious correlation which may arise when indices are used in the measurement of organs. Proc R Soc Lond 1896; 60: 489-98.
64. Rakic P. Specification of cerebral cortical areas. Science 1988; 241: 170-6.
65. Ramírez-Ruiz B, Martí MJ, Tolosa E, Giménez M, Bargalló N, Valldeoriola F, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007; 14: 750-6.
66. Reitan RM, Wolfson D, editors. The Halstead-Reitan neuropsychological test battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press; 1985.
67. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage 2010; 53: 1181-96.
68. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012; 61: 1402-18.
69. Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 10-5.
70. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, et al. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002; 58: 695-701.
71. Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RSR, Busa E, et al. Thinning of the cerebral cortex in aging. Cereb Cortex 2004; 14: 721-30.
72. Sanchez-Ramos JR, Ortoll R, Paulson GW. VIsual hallucinations associated with parkinson disease. Arch Neurol 1996; 53: 1265-8.
73. Sanfilipo MP, Benedict RHB, Zivadinov R, Bakshi R. Correction for intra-cranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage 2004; 22: 1732-43.
74. Schmidt M. Rey auditory verbal learning test: a handbook. Los Angeles, CA: Western Psychological Services; 1996.
75. Ségonne F, Pacheco J, Fischl B. Geometrically accurate topology-correction of cortical surfaces using nonseparating loops. IEEE Trans Med Imaging 2007; 26: 518-29.
76. Ségonne F, Dale A, Busa E, Glessner M, Salat D, Hahn H, et al. A hybrid approach to the skull stripping problem in MRI. Neuroimage 2004; 22: 1060-75.
77. Shulman KI, Pushkar Gold D, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: a longitudinal study. Int J Geriatr Psychiatry 1993; 8: 487-96.
78. Singh-Manoux A, Dugravot A, Ankri J, Nabi H, Berr C, Goldberg M, et al. Subjective cognitive complaints and mortality: Does the type of complaint matter? J Psychiatr Res 2014; 48: 73-8.
79. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87-97.
80. Song SK, Lee JE, Park H-J, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord 2011; 26: 289-96.
81. Tae W, Kim S, Joo E, Han S, Kim I, Kim S, et al. Cortical thickness abnormality in juvenile myoclonic epilepsy. J Neurol 2008; 255: 561-6.
82. Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopa-minergic probe. Arch Gen Psychiatry 2005; 62: 1228-36.
83. von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 2005; 15: 473-90.
84. Wechsler D. Wechsler adult intelligence scale-III (WAIS-III). New York, NY: Psychological Corporation; 1997.
85. Wechsler D. Wechsler abbreviated scale of intelligence (WASI). San Antonio, TX: Psychological Corporation; 1999.
86. Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf A, Duda J, et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011; 68: 1562-8.
87. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; 130: 1787-98.